Skip to main content
Equibles
ENTA logo

ENTA · Enanta Pharmaceuticals Inc

Track ENTA — free

Use ENTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.99 -0.21 (-1.88%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$320.09M
Shares
29.13M
Volume · Nov 13 127.7K Avg daily vol (3M) 261.95K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.99 Open$11.19 Day$10.51–11.66 52W close$10.08–16.85 Avg vol 30d245K Short int1.9M · 6.4% of shares · 7.6d Short vol50% Last earningsNov 25, 2024 DataJan 2020–Nov 2026 Filing10-Q · Aug 12

Up next

Q2 2024 earnings call transcript
call held May 6, 2024

Latest documents

2026
Oct 29
Current report 8-K
Other events

On October 29, 2026, the UPC invalidated European Patent No. EP 4 051 265 and found Enanta Pharmaceuticals’ Pfizer infringement action concerning Paxlovid unfounded.

Oct 28
Current report 8-K
Director or officer change, or executive pay, Regulation FD disclosure

Enanta Pharmaceuticals announced Jay R. Luly will retire as President and CEO by February 1, 2027 and remain Strategic Advisor for the remainder of 2027. Tara L. Kieffer was appointed Chief Operating Officer, while the Board searches internal and external candidates for Luly’s successor.

Aug 12
Quarterly report 10-Q FY2026 Q3, ended Jun 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $14.36M ▼ 21.6% Net loss $19.5M Diluted EPS -$0.67
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$65.26M
Trailing 12 months
Net income (TTM)
−$63.23M
Trailing 12 months
Revenue growth YoY
-21.6%
Year over year
Operating margin
-90.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$33.42M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.1%
Year over year · more shares
Price change (1Y)
-6.2%
Trailing year
Short interest
6.4%
Latest settlement · 7.6 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼22.8% $14.61M −$28.82M '24 Q4* ▼5.8% $16.96M −$22.29M '25 Q1 ▼12.5% $14.93M −$22.64M '25 Q2 ▲1.9% $18.31M −$18.25M '25 Q3 ▲3.5% $15.12M −$18.70M '25 Q4* ▲9.8% $18.61M −$11.94M '26 Q1 ▲15% $17.16M −$13.09M '26 Q2 LATEST ▼21.6% $14.36M −$19.50M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −8%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 13%
near low
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −19%
trailing
YTD return −30%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
95 of 122 funds reported for Sep 30 · net +301.5K sh shares · +12 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.37% of shares out · ▼ -18.0% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
122 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
Revenue growth +16%
Y/Y
EPS growth +30%
Y/Y
Free cash flow $-32.2M
Quant / Vol
risk profile
Very High
Volatility 49%
annualized · 1-yr
Max drawdown −40%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 6, 2020
HCV sales · calendar 2020 $2.3B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
13% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow Accumulating
95 of 122 funds reported for Sep 30 · net +301.5K sh shares · +12 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.37% of shares out · ▼ -18.0% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
122 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10 Now $11 · 13% Range high $17
vs 200-day avg -16% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and short-term and long-term marketable securities $211.5M fiscal third quarter ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENTA
Enanta Pharmaceuticals Inc
this stock
$320.09M -30.3% +16.5% — 6.4%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
126
% held
94.8%
Reported
95 of 122
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
182
View
Short & Settlement
Short Interest Falling
Shares short
1.9M
Days to cover
7.6d
Change
-408.6K sh
View
Short Volume
Short vol %
50%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$13
As of
Oct 2, 2026
View
Off-Exchange
Off-exchange %
38.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 12, 2023
View
Financials
Financials
Revenue (FY)
$65.3M
Net income (FY)
$-81.9M
EPS diluted
$-3.84
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 29, 2026
This year
19

On October 29, 2026, the UPC invalidated European Patent No. EP 4 051 265 and found Enanta Pharmaceuticals’ Pfizer infringement action concerning Paxlovid unfounded.

View
Proposed Sales
Value
$67.5K
Shares
4.7K
Filed
Dec 5, 2025
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View
Investor Relations
Latest news
Enanta Pharmaceuticals Announces…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
ENTA -0.1% -1.0% -18.8% +2.6% -30.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.7% +0.2% -19.3% +2.8% -40.9%
Key facts CIK 1177648 CUSIP 29251M106 13F (30d) 94 filings 80 filers Visit website Investor relations